

## Effects of Aluminium on $\beta$ -Amyloid (1–42) and Secretases (APP-Cleaving Enzymes) in Rat Brain

Linping Wang · Jiali Hu · Yue Zhao ·  
Xiaoting Lu · Qinli Zhang · Qiao Niu

Received: 25 December 2013 / Revised: 16 April 2014 / Accepted: 21 April 2014 / Published online: 3 May 2014  
© Springer Science+Business Media New York 2014

**Abstract** Chronic administration of aluminium has been proposed as an environmental factor that may affect some pathological changes related to neurotoxicity and Alzheimer's disease (AD). The abnormal generation and deposition of  $\beta$ -amyloid (A $\beta$ ) in senile plaques are hallmark features in the brains of AD patients. Furthermore, A $\beta$  is generated by the sequential cleavage of the amyloid precursor protein (APP) via the APP cleaving enzyme ( $\alpha$ -secretase, or  $\beta$ -secretase) and  $\gamma$ -secretase. In the present study, we investigated the modulation of A $\beta$  deposition and neurotoxicity in aluminium-maltolate-treated (0, 15, 30, 45 mmol/kg body weight via intraperitoneal injection) in experimental rats. We measured A $\beta$ 1–40 and A $\beta$ 1–42 in the cortex and hippocampus in rat brains using ELISA. Subtypes of  $\alpha$ -secretase,  $\beta$ -secretase, and  $\gamma$ -secretase, including ADAM9, ADAM10, ADAM17 (TACE), BACE1, presenilin 1 (PS1) and nicastrin (NCT), were determined using western blotting analyses. These results indicated that aluminium-maltolate induced an AD-like behavioural deficit in rats at 30 and 45 mmol/kg body weight. Moreover, the A $\beta$ 1–42 content increased significantly, both in the cortex and hippocampus, although no changes were observed in A $\beta$ 1–40. Furthermore, ADAM9, ADAM10, and ADAM17 decreased significantly; in contrast, BACE1, PS1, and NCT showed significant increase. Taken together, these results suggest that the changes in secretases may correlate to the abnormal deposition of A $\beta$  by aluminium in rat brains.

**Keywords** Aluminium ·  $\beta$ -Amyloid ·  $\alpha$ -Secretase ·  $\beta$ -Secretase ·  $\gamma$ -Secretase

### Introduction

Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterised by the progressive loss of memory and cognitive ability [1]. The pathogenesis of AD involves a key event of changes in the morphology of the amyloid- $\beta$  (A $\beta$ ) peptide, from its soluble monomeric form into fibrillated aggregates in the brain [2]. The excessive production and accumulation of A $\beta$  plays a critical role in the pathogenesis of AD at early stages and may represent a common pathway to AD induced by various factors [3–5]. Aluminium is a common chronic neurotoxin, and considerable evidence supports the possibility that it is a possible risk factor for AD [3, 6–10]. It is also known that as an element, aluminium accelerates A $\beta$  generation and aggregation, induces structural changes of A $\beta$ , and increases the formation of A $\beta$  oligomers [11–13].

Amyloid- $\beta$ , the primary component of amyloid plaques, is produced from amyloid precursor protein (APP) via a series of protease cleavages, including  $\beta$ - and  $\gamma$ -secretases [3]. APP is a transmembrane glycoprotein consisting of a large extracellular domain, a short transmembrane domain, and a cytoplasmic tail.  $\beta$ -secretase cleaves APP between amino acids 671 and 672 and produces sAPP $\beta$  and C99, while  $\gamma$ -secretase cleaves C99 in at amino acids 711–714 [14]. The key step in the generation of A $\beta$  is the cleavage of APP by  $\beta$ -secretases [beta-site APP-cleaving enzyme 1 (BACE1)] [3]. Furthermore, APP is also cleaved by  $\alpha$ -secretases within the A $\beta$  region and produces sAPP $\alpha$  and C83, which preclude the formation of A $\beta$  [15, 16]. In addition,  $\alpha$ -secretase appears to compete with  $\beta$ -secretase for the initial cleavage of APP but has opposite effects on A $\beta$  generation [17]. Thus the expression and activity of both of these enzymes may affect the level of A $\beta$ .

L. Wang · J. Hu · Y. Zhao · X. Lu · Q. Zhang · Q. Niu (✉)  
School of Public Health, Shanxi Medical University,  
Taiyuan 030001, Shanxi, China  
e-mail: niuqiao55@163.com

More than 20 years ago, Esch [18] described, for the first time, that APP is cleaved within the A $\beta$  sequence by an unknown protease, which was called secretase and is now known as  $\alpha$ -secretase. The initial protease  $\alpha$ -secretase was shown to have characteristics of a metalloprotease [19], and different metalloproteases were suggested as potential constitutive  $\alpha$ -secretases. The best studied  $\alpha$ -secretases were members of the ADAM (a disintegrin and metalloprotease) family, in particular ADAM9, ADAM10 and ADAM17 [20], which together constitute  $\alpha$ -secretase activity and mediate non-amyloidogenic  $\alpha$ -processing of APP [21].

BACE1 is a type 1 transmembrane aspartic protease that is related to the pepsin and retroviral aspartic protease families. BACE1 activity has a low optimum pH, and the enzyme is predominantly localised in acidic intracellular compartments. Soon after the discovery of BACE1, a homologous protein, BACE2, was identified. BACE1 and BACE2 share 64 % amino acid sequence homology and thus raise the possibility that BACE2 is also a  $\beta$ -secretase. However, unlike BACE1, which is highly expressed in neurons of the brain, BACE2 is expressed at low levels in the brain and does not exhibit the same cleavage specificity for APP as BACE1, thus indicating that it is a poor  $\beta$ -secretase candidate.

$\gamma$ -secretase is a multisubunit intramembranous protein complex consisting of at least four proteins; presenilin (PS), nicastrin (NCT), anterior pharynx defective-1 (Aph-1) and presenilin enhancer-2 (Pen-2) [22]. Presenilin is a central, catalytic component of the  $\gamma$ -secretase complex, which induces intramembrane cleavage of various protein substrates [23]. Nicastrin is a large protein, which contains a single transmembrane domain. NCT is itself not catalytically active but instead promotes the maturation and proper trafficking of other components of the  $\gamma$ -secretase complex. PEN-2, which contains 101 amino acids, is the smallest subunit of the  $\gamma$ -secretase complex and shares no significant domain homology with any other known protein family [24]. APH-1 protein has seven transmembrane domains and potentially acts as a scaffold for complex formation. In addition, APH-1 has been shown to contribute to the proper assembly of the complex. Furthermore,  $\gamma$ -secretase is the final protease in the course of A $\beta$  generation, and its amount and activity can affect the generation and aggregation of A $\beta$ .

However, whether  $\alpha$ -,  $\beta$ -,  $\gamma$ -secretases are all involved in Al-induced elevation and aggregation of A $\beta$  is still unknown. Because the hippocampus and cerebral cortex in humans and rodents can accumulate A $\beta$ , they are considered to be AD vulnerable regions [25]. Thus, in the present study, changes in A $\beta$ 1–40 and A $\beta$ 1–42 in the hippocampus and cerebral cortex in aluminium-maltolate treated neurotoxic rats were shown. We also analysed the contents of

amyloidogenic-secretase BACE1; non-amyloidogenic secretases, ADAM9, ADAM10 and ADAM17; presenilin1; and NCT in brain extracts in response to aluminium-maltolate exposure.

## Materials and Methods

### Materials

AlCl<sub>3</sub>·6H<sub>2</sub>O (purity 99 %) and maltolate (purity 99 %) were purchased from Sigma-Aldrich Chemical Co. (Steinheim, Germany). Rat A $\beta$ 1–40 and A $\beta$ 1–42 ELISA kits were obtained from Usen Life Science, Inc. (Wuhan, China). The BCA protein quantitative kit, IgG (H+L), ECL western blot Kit, and anti- $\beta$ -actin antibody were obtained from Beijing CoWin Bioscience Co. Ltd. (Beijing, China). The anti-ADAM9 antibody was purchased from Signaling Technology, Inc. (Boston, USA), and the anti ADAM17 antibody was purchased from Abcam Inc. (Cambridge, England). The anti-ADAM10, BACE1, PS1 and NCT antibodies were obtained from Epitomics, Inc. (California, USA). All chemicals were of analytical grade unless otherwise indicated.

### Al(mal)<sub>3</sub> Preparation

Al(mal)<sub>3</sub> was prepared according to previously described methods [26]. AlCl<sub>3</sub>·6H<sub>2</sub>O was dissolved in distilled water to a final concentration of 90 mmol/L, and maltolate was dissolved in phosphate-buffered saline (PBS) to a final concentration of 270 mmol/L. Two solutions were then mixed in equal volumes, and the pH was adjusted to 7.4 with 1 mol/L NaOH. The Al(mal)<sub>3</sub> solution used in the animal experiments was freshly prepared for each experiment, and all solutions were sterile filtered using 0.22  $\mu$ m syringe filters immediately following preparation.

### Animals

Forty male adult Sprague-Dawley (SD) rats (200–220 g) were supplied by the Experimental Animal Center of Shanxi Medical University (Taiyuan, China). The rats were housed with free access to food and water in a room with an ambient temperature of 22  $\pm$  2 °C and a 12:12 h light/dark cycle. All experiments were performed strictly according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Animals were induced using aluminium-maltolate. The animals were randomly assigned to four groups: control groups with saline treatment and Al(mal)<sub>3</sub> groups with 15 mmol/kg BW, 30 mmol/kg BW, or 45 mmol/kg BW. Saline and Al(mal)<sub>3</sub> were administered to the rats via intraperitoneal

injections. Administration was performed daily for 2 months and at the same time every day.

### Morris Water Maze

The Morris water maze consisted of a black pool (200 cm in diameter, 75 cm high, and 45 cm above floor level) filled with water, and a black platform (10 cm in diameter, 50 cm high) was submerged 1 cm below the water surface and placed in the centre of the Southwest quadrant. The four starting locations were labelled North (N), East (E), South (S), and West (W) at an equal distance from the rim. The water was maintained at  $22 \pm 2$  °C, and the platform was placed in either one of four virtual quadrants at 20 cm from the sidewall. The movements of the rats were recorded using a video camera connected to a computer. Data were analysed using a tracking program (version 1.0.0.3, Pharmaceutical Institute of the Academy of Medical Science of China, Beijing, China). Over four consecutive days at 7 a.m., the rats were trained four times per day and given a maximum of 120 s to locate the hidden platform. Once the platform was found, the rats were allowed to stay on the platform for 30 s. Rats that failed to locate the platform were then placed on it. Each rat was gently placed into the water with their nose facing the wall at one of the starting points. All of the animals were tested in sequence, and the time interval between two trials was approximately 1–1.5 h. The animals were placed in the same starting points on each day. The escape latency was averaged from four trials per day. The platform was removed from the pool on the 5th day, and the average frequency in finding the location of the platform in all rats was recorded in 120 s.

### Sample Preparation

After the Morris water maze test, the rats were anaesthetised, perfused and sacrificed. The brains were rapidly removed from the skulls and dissected into different regions. All subsequent operations were performed on ice and the samples were frozen in cryogenic refrigerators at  $-80$  °C for further analysis. Rat cortical and hippocampal tissues were homogenised and solubilised in lysis buffer (Beijing CoWin Bioscience Co. Ltd, Beijing, China). Protein concentrations were determined using the BCA Kit (Beijing CoWin Bioscience Co. Ltd, Beijing, China).

### Detection for Aluminium Levels in the Rat Brain

The cortical (Co) and hippocampal (Hi) tissues of the rats were digested using a microwave. Detection for aluminium levels in rat brains were performed using graphite furnace atomic absorption spectrometry (gfaas).

### ELISA for A $\beta$ 1–40, and A $\beta$ 1–42 Proteins

All experimental procedures were performed according to the manufacturer's instructions.

### Western Blotting Analyses for APP, ADAM9, ADAM10, ADAM17, BACE1, PS1 and NCT

Proteins (30  $\mu$ g) were separated using 10 % sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and were then transferred onto a polyvinylidene difluoride (PVDF) membrane. The membrane was incubated with antibodies directed against the following proteins: APP (1:1,000); ADAM9 (1:1,000), ADAM10 (1:1,000); ADAM17 (1:2,000); BACE1 (1:2,000); PS1 (1:1,000); and NCT (1:1,000). Immunoreactive proteins were visualised by exposure to X-ray film. The protein bands were quantified using image scanning, and the optical density was measured using computer software (Image lab 3.0, Bio-Rad Laboratories, Inc., California, USA). The data were then corrected by background subtraction and normalised against  $\beta$ -actin as an internal control.


### Data Analyses

Statistical analysis of the data was performed using SPSS 17.0. All results were expressed as the mean  $\pm$  SEM. Behavioural tests were analysed using repeated measure and one-way ANOVA. The level of proteins was analysed using one-way ANOVA, followed by the post hoc Dunnett test. The correlation between the expression of proteins and A $\beta$  was assessed using Pearson correlation analyses. The criterion for statistical significance was established at  $P < 0.05$ .

## Results


### Behavioural Results

None of the tested mice showed obvious health problems (e.g., weight loss, cataracts, or toxicity reaction). During the 4-day acquisition phase of the Morris water maze test, the escape latency of all rats in the platform quadrant gradually improved, and the escape latency of Al(mal)<sub>3</sub>-treated rats was longer compared to the control rats ( $F(3,39) = 4.887$ ,  $P < 0.01$ , Fig. 1(1)). Consistent with the results of the escape latency, the average frequency in finding the platform within 120 s in normal rats was markedly higher compared to Al(mal)<sub>3</sub> rats on the 5th day



**Fig. 1** SD rats were treated with aluminium-maltolate at 0, 15, 30, and 45 mmol/kg BW, i.p. The Morris water maze test was applied after treatment. Repeated measure analysis; one-way ANOVA,

$n = 10$  for each group; error bars indicate the SEM.  $*P < 0.05$  indicates the significant difference compared to control



**Fig. 2** Aluminium levels in the rat hippocampus (Hippo) and cortex (CTX) were measured after aluminium-maltolate treatment using gfaas. Each experiment consisted of three parallel samples. One-way ANOVA,  $n = 10$  for each group; error bars indicate the SEM.  $*P < 0.05$  indicates the significant difference compared to control

( $F(3,39) = 9.575, P < 0.01$ , Fig. 1(2)). The results of the Morris water maze test demonstrated a longer escape latency and reduced frequency in finding the platform in the  $Al(mal)_3$  rats, indicating that  $Al(mal)_3$  affected learning and memory.

**Aluminium Levels in Rat Brains**

As shown in Fig. 2, the levels of aluminium increased significantly in both Co and Hi compared to control expression ( $F(3,39) = 82.475, P < 0.01$  for Co,  $F(3,39) = 94.065, P < 0.01$  for Hi).

**Aβ1–40 and Aβ1–42 Protein Levels**

As shown in Fig. 3, there was no significant difference in the Aβ1–40 content between the Co and Hi of the  $Al(mal)_3$ -treated rats and control rats ( $F(3,39) = 0.880, P > 0.05$  for Co,  $F(3,39) = 1.590, P > 0.05$  for Hi, Fig. 3(1)). In contrast, a significant increase in Aβ1–42 expression was observed in both Co and Hi ( $F(3,39) = 6.442, P < 0.01$  for Co,  $F(3,39) = 29.908, P < 0.01$  for Hi, Fig. 3(2)).

**APP Protein Expression**

The expression of APP increased in both Co and Hi compared to control expression ( $F(3,39) = 81.325, P < 0.05$  for Co,  $F(3,39) = 95.600, P < 0.05$  for Hi, Fig. 4(1),(2),(3)). Statistical analyses showed that the expression of APP did not correlate with the content of Aβ1–42 ( $R = 0.294, P > 0.05$  for Co;  $R = 0.353, P > 0.05$  for Hi).



**ADAM9, ADAM10 and ADAM17 Protein Expression**

As shown in Fig. 5, the expression of ADAM9 decreased in the Co of  $Al(mal)_3$ -treated rats but was not significant compared to the control group ( $F(3,39) = 0.609, P > 0.05$ , Fig. 5(1),(3)); it did not correlate with Aβ1–42 ( $R = -0.134, P > 0.05$ ) and decreased significantly in the Hi ( $F(3,39) = 11.368, P < 0.01$ , Fig. 5(2),(3)). Statistical analysis showed that the expression of ADAM9 correlated with the content of Aβ1–42 ( $R = -0.761, P < 0.01$ ). Furthermore, ADAM10 was significantly reduced in both tissues ( $F(3,39) = 67.177, P < 0.01$  for Co,  $F(3,39) = 81.093, P < 0.01$  for Hi, Fig. 5(1),(2),(4)). Statistical analysis also revealed that the expression of ADAM10 correlated with the content of Aβ1–42 ( $R = -0.708, P < 0.01$  for Co;  $R = -0.897, P < 0.01$  for Hi). ADAM17 was significantly reduced in both tissues ( $F(3,39) = 142.223, P < 0.01$  for Co,  $F(2,39) = 5.119, P < 0.01$  for Hi, Fig. 5(1),(2),(5)). Statistical analysis showed that the expression of ADAM17 correlated with the level of Aβ1–42 ( $R = -0.634, P < 0.01$  for Co;  $R = -0.718, P < 0.01$  for Hi).

**BACE1 Protein Expression**

The expression of BACE1 increased significantly in both Co and Hi compared to control expression ( $F(3,39) = 62.200, P < 0.01$  for Co,  $F(3,39) = 114.318, P < 0.05$  for Hi, Fig. 6(1),(2),(3)). Statistical analysis showed that the expression of BACE1 correlated with the content of Aβ1–42 ( $R = 0.608, P < 0.01$  for Co;  $R = 0.804, P < 0.01$  for Hi).

**Fig. 3** Aβ content in the rat Hippo and CTX were measured after aluminium-maltolate treatment using ELISA. Each experiment consisted of three parallel samples. One-way ANOVA, n = 10 for each group; error bars indicate the SEM. \*P < 0.05 indicates a significant difference compared to control



**Figs. 4–7** Proteins of Aβ metabolism-related molecules from the rat Hippo and CTX were measured after aluminium-maltolate treatment using western blotting analyses. β-actin was used as the loading control. All experiments were performed at least in triplicate with

independent experiments. One-way ANOVA, n = 10 for each group; error bars indicate the SEM. \*P < 0.05 indicates a significant difference compared to control

**PS1 and NCT Protein Levels**

The protein expression of PS1 was significantly increased in both tissues ( $F(3,39) = 79.720, P < 0.01$  for Co,  $F(3,39) = 30.614, P < 0.01$  for Hi, see Fig. 7(1),(2),(3)), and was significantly correlated with Aβ1–42 ( $R = 0.744, P < 0.01$  for Co;  $R = 0.757, P < 0.01$  for Hi).

However, the expression of NCT was significantly increased in both tissues ( $F(3,39) = 26.147, P < 0.01$  for Co,  $F(3,39) = 241.001, P < 0.05$  for Hi, see Fig. 7(1),(2),(4)). Statistical analysis showed that the expression of NCT correlated significantly with the content of Aβ1–42 ( $R = 0.622, P < 0.01$  for Hi;  $R = 0.859, P < 0.01$  for Co).

## Discussion

Epidemiological studies have revealed an association between chronic exposure to aluminium in drinking water and AD risk [27, 28]. Aluminium can reach and accumulate in nearly every organ in the human body, and the central nervous system is a specific target of deleterious effects [29]. Various mechanisms have been proposed to underlie aluminium-induced neurotoxicity, such as oxidative stress [30], alterations of the phosphorylation levels of neurofilaments [31], among other mechanisms. However, the contribution of aluminium to AD still requires further investigation. During the development of AD, extracellular accumulation of A $\beta$  in the brain is regarded as an early and main event that occurs when massive cell death is not observed [31]. Importantly, aluminium has been found to enhance the production and aggregation of A $\beta$  both in *in vitro* and *in vivo* studies [11, 32]; however, its underlying mechanism remains unknown.

The present study revealed that aluminium-maltolate could enter the brain in rats and damage learning and memory functions as well as enhance the A $\beta$ 1–42 content in the cortex and hippocampus. Moreover, aluminium-maltolate induced A $\beta$ 1–42 increase in the hippocampus is more profound compared to the cortex (Fig. 4). Furthermore, evidence showed that aluminium may be involved in the deposition of A $\beta$  peptides, which causes severe damage to brain tissues [33, 34]. A $\beta$  exists in a dynamic equilibrium of soluble monomeric, oligomeric, protofibrillar, and fibrillar forms, and the levels of which reflect a balance between their production and removal from the brain. A $\beta$ 1–42 is relatively insoluble in the interstitial fluid and is prone to parenchymal deposition, whereas A $\beta$ 1–40 is more soluble and less prone to parenchymal deposition. In our study, aluminium increased A $\beta$ 1–42 compared to A $\beta$ 1–40 in rat brains (Fig. 4). On the basis, the possible reason which aluminium increased A $\beta$ 1–42 in rat brains, rather than A $\beta$ 1–40 was that A $\beta$ 1–40 is more soluble and less prone to parenchymal increasing.

An increasing number of reports has shown that the amount of A $\beta$  in the brain is correlated to A $\beta$  generation [35]. Thus, it was suggested that an alteration in the expression of metabolism-associated molecules of A $\beta$  might be developed into early markers of aluminium neurotoxicity. In our study, aluminium increased the expression of APP, but these changes did not correlate with the content of A $\beta$ 1–42. In addition, the present study showed that the expression of enzymes that participate in A $\beta$  metabolism obviously changed: (1) ADAM9, ADAM10 and ADAM17 were decreased; (2) BACE1 was increased; and (3) PS1 and NCT were increased. In addition, they correlated with the content of A $\beta$ 1–42 in rat brains. This finding suggested that, in addition to A $\beta$ , A $\beta$ -

pathway-related molecules, such as ADAM, BACE1, PS1 and NCT, could also be developed into critical biological markers for aluminium neurotoxicity.

Evidence showed that the protease ADAM10 but not ADAM9 or ADAM 17 was essential for  $\alpha$ -secretase cleavage. Moreover, ADAM9 and ADAM17 were not able to compensate for ADAM10 in constitutive  $\alpha$ -secretase cleavage [17]. Furthermore, ADAM10 showed coordinated expression with APP in the human brain [36]. In a subset of ADAM10-deficient fibroblasts, APP  $\alpha$ -secretase cleavage was altered to a variable degree [17]. In our study, the decrease in ADAM9, ADAM10 and ADAM17 were obvious in the hippocampus compared to the cortex, and the decrease in ADAM10 was most profound in both the cortex and hippocampus. This appearance was similar to A $\beta$ 1–42. Taken together, these results suggested that the damage induced by aluminium on the hippocampus was more serious compared to the cortex. Furthermore, the decrease in ADAM9, 10, and 17 played a role in the increase in A $\beta$ 1–42 induced by aluminium. In the hippocampus and cortex of AD patients, ADAM17 was localised to senile plaques [37]. Evidence has shown that although ADAM17 is capable of cleaving APP, it is likely that additional members of the ADAM family mediate the endogenous constitutive and regulated  $\alpha$ -secretase cleavage of APP in HEK293 cells [16]. In the present study, the decrease in ADAM17 may be one of the enzymes that regulate  $\alpha$ -secretase cleavage of APP. Although the involvement of ADAM9 is less convincing, emerging evidence has demonstrated that there is most likely not a single  $\alpha$ -secretase activity but rather several enzymes activities that act together to cleave APP at the  $\alpha$ -secretase site. The decrease in ADAM9 was not profound compared to ADAM10 and ADAM17. We proposed that the role of ADAM9 is still unclear or that there may be a functional overlap or redundancy with other members of the ADAMs family in aluminium-treated rats.

BACE1 cleavage is a pre-requisite for A $\beta$  formation and is the initiating step in A $\beta$  generation. BACE1 levels are elevated in both AD experimental models and in the AD patient brain [38–40]. Moreover, BACE1 activity is correlated with brain A $\beta$  production in the frontal cortex [41, 42]. Intraventricular Al-maltol injection in the aged New Zealand white rabbit induced behavioural, biochemical and neuropathological changes, which were similar to what occurs in clinical AD, including A $\beta$  deposition close to the cerebral cortex and hippocampus and increased  $\beta$ -secretase activity in the hippocampus [43]. In addition, there was a marked increase in  $\beta$ -secretase and amyloid- $\beta$  induced by AlCl<sub>3</sub> [13]. Differentiated neuronal SH-SY5Y cells exposed to AlCl<sub>3</sub> and A $\beta$  demonstrated slightly reduced BACE1 levels after 1 h and significantly increased BACE1 levels after 3 h of exposure. Moreover, BACE2 levels were

increased at both times. The mRNA levels of both genes were downregulated with longer time periods of exposure (6, 12, and 24 h). Taken together, these findings indicated that aluminium toxicity is correlated with changes in both BACE1 and BACE2 expression levels [3]. In our study, BACE1 was detected and changes in BACE1 showed a positive correlation with changes in brain A $\beta$ 42. Consistent with other studies, our data suggested that the increase in BACE1 expression might be a key factor of aluminium-induced A $\beta$ 1–42 content in the rat brain.

$\gamma$ -secretase, an intramembrane aspartyl protease, is critically involved in AD via proteolysis of the APP, which generates the pathogenic and amyloid plaque-forming A $\beta$ 1–42 peptide [44]. However, it is not completely clear how the different subunits of  $\gamma$ -secretase contribute to substrate docking and cleaving. It appears that the major obstacle lies in the lack of structural information related to the entire complex, which consists of four subunits [23]. PS was thought to be a central, catalytic moiety of the  $\gamma$ -secretase complex. Some studies found that PS1 was able to cleave substrates in the absence of NCT, APH1, and PEN-2 in an activity test performed in liposomes. However, NCT has been proposed to participate in the recruitment of Notch1 and APP substrates to  $\gamma$ -secretase [45, 46]. NCT was shown to co-localise with PS1 in murine lysosomes. Furthermore,  $\gamma$ -secretase activity against APP could also be detected in lysosomal membranes [47]. Moreover,  $\gamma$ -secretase was thought to be important for PS stabilisation and trafficking [48–50]. In addition, further evidence revealed that there was a key role for NCT in modulating A $\beta$  production and amyloid plaque formation in vivo [51]. In the present study, we investigated the levels of PS1 and NCT, which are different  $\gamma$ -secretase components, in the cortex and hippocampus of rat brains. Both PS1 and NCT increased and correlated well with A $\beta$ 1–42 levels. Our study indicated that PS1 and NCT played a role during the deposition of A $\beta$ 1–42 induced by aluminium-maltolate.

In conclusion, our findings suggested that aluminium-maltolate induced the depression of learning and memory in rats in vivo and generated a high content of A $\beta$ 1–42 in rat brains. Furthermore,  $\beta$ -secretase increased significantly, and different subtypes or components of  $\alpha$ -secretase (particularly ADAM10 and ADAM17) significantly decreased. Thus, APP cleavage by BACE1 was increased, and APP cleavage by  $\alpha$ -secretase was decreased. Consistent with these findings, C99 cleavage by increased subtype components of  $\gamma$ -secretase was increased in the aluminium-treated groups, and A $\beta$ 1–42 was produced and increased in the cortex and hippocampus of aluminium-treated animals. All of these factors may be developed into useful markers to detect the early neurotoxic effect of aluminium and can also be regarded as targets for a therapeutic strategy against

the neurotoxicity of aluminium. Furthermore, some of these factors may be developed into valid targets to treat AD due to aluminium neurotoxicity.

**Acknowledgments** This work was supported by the National Nature Science Foundation of China (81302410).

## References

1. Wu G, Sankaranarayanan S, Hsieh SH, Simon AJ, Savage MJ (2011) Decrease in brain soluble amyloid precursor protein beta (sAPPbeta) in Alzheimer's disease cortex. *J Neurosci Res* 89:822–832
2. Jiang T, Zhi XL, Zhang YH, Pan LF, Zhou P (2012) Inhibitory effect of curcumin on the Al(III)-induced A $\beta$ (4)(2) aggregation and neurotoxicity in vitro. *Biochim Biophys Acta* 1822:1207–1215
3. Castorina A, Tiralongo A, Giunta S, Carnazza ML, Scapagnini G, D'Agata V (2010) Early effects of aluminum chloride on beta-secretase mRNA expression in a neuronal model of beta-amyloid toxicity. *Cell Biol Toxicol* 26:367–377
4. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat Neurosci* 8:79–84
5. Banks WA, Niehoff ML, Drago D, Zatta P (2006) Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier. *Brain Res* 1116:215–221
6. Walton JR (2013) Aluminum involvement in the progression of Alzheimer's disease. *J Alzheimers Dis (JAD)* 35:7–43
7. Brenner S (2013) Aluminum may mediate Alzheimer's disease through liver toxicity, with aberrant hepatic synthesis of ceruloplasmin and ATPase7B, the resultant excess free copper causing brain oxidation, beta-amyloid aggregation and Alzheimer disease. *Med Hypotheses* 80:326–327
8. Walton JR (2012) Cognitive deterioration and associated pathology induced by chronic low-level aluminum ingestion in a translational rat model provides an explanation of Alzheimer's disease, tests for susceptibility and avenues for treatment. *Int J Alzheimers Dis* 2012:914947
9. Liang RF, Li WQ, Wang XH, Zhang HF, Wang H, Wang JX, Zhang Y, Wan MT, Pan BL, Niu Q (2012) Aluminium-maltolate-induced impairment of learning, memory and hippocampal long-term potentiation in rats. *Ind Health* 50:428–436
10. Ferreira PC, Piai Kde A, Takayanagui AM, Segura-Munoz SI (2008) Aluminum as a risk factor for Alzheimer's disease. *Rev Lat Am Enfermagem* 16:151–157
11. Ricchelli F, Drago D, Filippi B, Tognon G, Zatta P (2005) Aluminum-triggered structural modifications and aggregation of beta-amyloids. *Cell Mol Life Sci (CMLS)* 62:1724–1733
12. Drago D, Folin M, Baiguera S, Tognon G, Ricchelli F, Zatta P (2007) Comparative effects of A $\beta$ (1–42)-Al complex from rat and human amyloid on rat endothelial cell cultures. *J Alzheimers Dis (JAD)* 11:33–44
13. Zaky A, Mohammad B, Mofthah M, Kandeel KM, Bassiouny AR (2013) Apurinic/aprimidinic endonuclease 1 is a key modulator of aluminum-induced neuroinflammation. *BMC Neurosci* 14:26
14. Fiorelli T, Kirouac L, Padmanabhan J (2013) Altered processing of amyloid precursor protein in cells undergoing apoptosis. *PLoS One* 8:e57979
15. Deuss M, Reiss K, Hartmann D (2008) Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17. *Curr Alzheimer Res* 5:187–201

16. Allinson TM, Parkin ET, Turner AJ, Hooper NM (2003) ADAMs family members as amyloid precursor protein alpha-secretases. *J Neurosci Res* 74:342–352
17. Lichtenthaler SF (2011) Alpha-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. *J Neurochem* 116:10–21
18. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, McClure D, Ward PJ (1990) Cleavage of amyloid beta peptide during constitutive processing of its precursor. *Science (New York, NY)* 248:1122–1124
19. Roberts SB, Ripellino JA, Ingalls KM, Robakis NK, Felsenstein KM (1994) Non-amyloidogenic cleavage of the beta-amyloid precursor protein by an integral membrane metalloendopeptidase. *J Biol Chem* 269:3111–3116
20. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. *Proc Natl Acad Sci USA* 96:3922–3927
21. Delarasse C, Auger R, Gonnord P, Fontaine B, Kanellopoulos JM (2011) The purinergic receptor P2X7 triggers alpha-secretase-dependent processing of the amyloid precursor protein. *J Biol Chem* 286:2596–2606
22. Frykman S, Hur JY, Franberg J, Aoki M, Winblad B, Nahalkova J, Behbahani H, Tjernberg LO (2010) Synaptic and endosomal localization of active gamma-secretase in rat brain. *PLoS One* 5:e8948
23. Smolarkiewicz M, Skrzypczak T, Wojtaszek P (2013) The very many faces of presenilins and the  $\gamma$ -secretase complex. *Protoplasma* 250:997–1011
24. Dries DR, Yu G (2008) Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease. *Curr Alzheimer Res* 5:132–146
25. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. *Neurobiol Aging* 26:645–654
26. Langui D, Probst A, Anderton B, Brion JP, Ulrich J (1990) Aluminium-induced tangles in cultured rat neurones. Enhanced effect of aluminium by addition of maltol. *Acta Neuropathol* 80:649–655
27. Flaten TP (2001) Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water. *Brain Res Bull* 55:187–196
28. Martyn CN (1992) The epidemiology of Alzheimer's disease in relation to aluminium. *Ciba Found Symp Ciba* 169:69–79 discussion 79–86
29. Chen TJ, Hung HS, Wang DC, Chen SS (2010) The protective effect of Rho-associated kinase inhibitor on aluminum-induced neurotoxicity in rat cortical neurons. *Toxicol Sci* 116:264–272
30. Bhalla P, Dhawan DK (2009) Protective role of lithium in ameliorating the aluminium-induced oxidative stress and histological changes in rat brain. *Cell Mol Neurobiol* 29:513–521
31. Kaur A, Joshi K, Minz RW, Gill KD (2006) Neurofilament phosphorylation and disruption: a possible mechanism of chronic aluminium toxicity in Wistar rats. *Toxicology* 219:1–10
32. Campbell A, Kumar A, La Rosa FG, Prasad KN, Bondy SC (2000) Aluminum increases levels of beta-amyloid and ubiquitin in neuroblastoma but not in glioma cells. *Proc Soc Exp Biol Med (New York, NY)* 223:397–402
33. Yumoto S, Kakimi S, Ohsaki A, Ishikawa A (2009) Demonstration of aluminum in amyloid fibers in the cores of senile plaques in the brains of patients with Alzheimer's disease. *J Inorg Biochem* 103:1579–1584
34. Pratico D, Uryu K, Sung S, Tang S, Trojanowski JQ, Lee VM (2002) Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. *FASEB J* 16:1138–1140
35. Sun ZZ, Chen ZB, Jiang H, Li LL, Li EG, Xu Y (2009) Alteration of Abeta metabolism-related molecules in predementia induced by AIC3 and D-galactose. *Age* 31:277–284
36. Marcinkiewicz M, Seidah NG (2000) Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. *J Neurochem* 75:2133–2143
37. Skovronsky DM, Fath S, Lee VM, Milla ME (2001) Neuronal localization of the TNFalpha converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. *J Neurobiol* 49:40–46
38. Harada H, Tamaoka A, Ishii K, Shoji S, Kametaka S, Kametani F, Saito Y, Murayama S (2006) Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. *Neurosci Res* 54:24–29
39. Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R (2007) Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. *J Neurosci* 27:3639–3649
40. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmo M, Santoro G, Davit A, Danni O, Smith MA, Perry G, Tabaton M (2005) Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. *J Neurochem* 92:628–636
41. Li Q, Sudhof TC (2004) Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. *J Biol Chem* 279:10542–10550
42. Gustaw KA, Garrett MR, Lee HG, Castellani RJ, Zagorski MG, Prakasam A, Siedlak SL, Zhu X, Perry G, Petersen RB, Friedland RP, Smith MA (2008) Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. *J Neurochem* 106:1350–1356
43. Panahi N, Mahmoudian M, Mortazavi P, Hashjin GS (2013) Effects of berberine on beta-secretase activity in a rabbit model of Alzheimer's disease. *Arch Med Sci (AMS)* 9:146–150
44. Hass MR, Sato C, Kopan R, Zhao G (2009) Presenilin: RIP and beyond. *Semin Cell Dev Biol* 20:201–210
45. Chen F, Yu G, Arawaka S, Nishimura M, Kawarai T, Yu H, Tandon A, Supala A, Song YQ, Rogaeva E, Milman P, Sato C, Yu C, Janus C, Lee J, Song L, Zhang L, Fraser PE, St George-Hyslop PH (2001) Nicastrin binds to membrane-tethered Notch. *Nat Cell Biol* 3:751–754
46. Dries DR, Shah S, Han YH, Yu C, Yu S, Shearman MS, Yu G (2009) Glu-333 of nicastrin directly participates in gamma-secretase activity. *J Biol Chem* 284:29714–29724
47. Pasternak SH, Bagshaw RD, Guiral M, Zhang S, Ackerley CA, Pak BJ, Callahan JW, Mahuran DJ (2003) Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. *J Biol Chem* 278:26687–26694
48. LaVoie MJ, Fraering PC, Ostaszewski BL, Ye W, Kimberly WT, Wolfe MS, Selkoe DJ (2003) Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. *J Biol Chem* 278:37213–37222
49. Zhang YW, Luo WJ, Wang H, Lin P, Vetrivel KS, Liao F, Li F, Wong PC, Farquhar MG, Thinakaran G, Xu H (2005) Nicastrin is critical for stability and trafficking but not association of other presenilin/gamma-secretase components. *J Biol Chem* 280:17020–17026
50. Mao G, Cui MZ, Li T, Jin Y, Xu X (2012) Pen-2 is dispensable for endoproteolysis of presenilin 1, and nicastrin-Aph subcomplex is important for both gamma-secretase assembly and substrate recruitment. *J Neurochem* 123:837–844
51. Sesele K, Thanopoulou K, Paouri E, Tsefou E, Klinakis A, Georgopoulos S (2013) Conditional inactivation of nicastrin restricts amyloid deposition in an Alzheimer's disease mouse model. *Aging cell* 12:1032–1040